Torrent Pharmaceuticals Limited - Asset Resilience Ratio
Torrent Pharmaceuticals Limited (TORNTPHARM) has an Asset Resilience Ratio of 2.79% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Torrent Pharmaceuticals Limited short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2026)
This chart shows how Torrent Pharmaceuticals Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Torrent Pharmaceuticals Limited (TORNTPHARM) total assets.
Liquid Assets Composition Over Time
This chart breaks down Torrent Pharmaceuticals Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Torrent Pharmaceuticals Limited's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs12.38 Billion | 2.79% |
| Total Liquid Assets | Rs12.38 Billion | 2.79% |
Asset Resilience Insights
- Limited Liquidity: Torrent Pharmaceuticals Limited maintains only 2.79% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Torrent Pharmaceuticals Limited Industry Peers by Asset Resilience Ratio
Compare Torrent Pharmaceuticals Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CHRISTINA LAKE CANNABIS
F:CLB |
Drug Manufacturers - Specialty & Generic | 0.19% |
|
Moberg Pharma AB (publ)
ST:MOB |
Drug Manufacturers - Specialty & Generic | 4.15% |
|
Wockhardt Limited
NSE:WOCKPHARMA |
Drug Manufacturers - Specialty & Generic | 5.19% |
|
PharmaBlock Sciences Nanjing Inc Class A
SHE:300725 |
Drug Manufacturers - Specialty & Generic | 11.01% |
|
AptaBio Therapeutics Inc
KQ:293780 |
Drug Manufacturers - Specialty & Generic | 1.57% |
|
Canopy Growth Corp
NASDAQ:CGC |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Zhejiang Nhu Co Ltd
SHE:002001 |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS
IS:ECILC |
Drug Manufacturers - Specialty & Generic | 0.46% |
Annual Asset Resilience Ratio for Torrent Pharmaceuticals Limited (2007–2026)
The table below shows the annual Asset Resilience Ratio data for Torrent Pharmaceuticals Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 2.79% | Rs12.38 Billion ≈ $133.89 Million |
Rs443.12 Billion ≈ $4.79 Billion |
+0.49pp |
| 2025-03-31 | 2.31% | Rs3.46 Billion ≈ $37.42 Million |
Rs149.90 Billion ≈ $1.62 Billion |
-1.28pp |
| 2024-03-31 | 3.59% | Rs5.40 Billion ≈ $58.43 Million |
Rs150.61 Billion ≈ $1.63 Billion |
+1.16pp |
| 2023-03-31 | 2.43% | Rs3.65 Billion ≈ $39.47 Million |
Rs150.12 Billion ≈ $1.62 Billion |
+0.85pp |
| 2022-03-31 | 1.58% | Rs2.07 Billion ≈ $22.43 Million |
Rs131.00 Billion ≈ $1.42 Billion |
+0.30pp |
| 2021-03-31 | 1.28% | Rs1.80 Billion ≈ $19.51 Million |
Rs140.75 Billion ≈ $1.52 Billion |
-0.54pp |
| 2020-03-31 | 1.83% | Rs2.56 Billion ≈ $27.71 Million |
Rs140.38 Billion ≈ $1.52 Billion |
-2.55pp |
| 2019-03-31 | 4.37% | Rs6.17 Billion ≈ $66.75 Million |
Rs141.21 Billion ≈ $1.53 Billion |
-7.90pp |
| 2018-03-31 | 12.27% | Rs17.47 Billion ≈ $188.97 Million |
Rs142.43 Billion ≈ $1.54 Billion |
-7.78pp |
| 2017-03-31 | 20.05% | Rs20.30 Billion ≈ $219.55 Million |
Rs101.25 Billion ≈ $1.09 Billion |
+11.62pp |
| 2016-03-31 | 8.43% | Rs7.60 Billion ≈ $82.22 Million |
Rs90.14 Billion ≈ $974.79 Million |
+4.67pp |
| 2015-03-31 | 3.76% | Rs2.98 Billion ≈ $32.18 Million |
Rs79.11 Billion ≈ $855.55 Million |
+0.10pp |
| 2014-03-31 | 3.66% | Rs1.86 Billion ≈ $20.08 Million |
Rs50.70 Billion ≈ $548.28 Million |
+2.06pp |
| 2013-03-31 | 1.60% | Rs604.40 Million ≈ $6.54 Million |
Rs37.83 Billion ≈ $409.10 Million |
-1.22pp |
| 2012-03-31 | 2.81% | Rs865.16 Million ≈ $9.36 Million |
Rs30.74 Billion ≈ $332.39 Million |
-2.79pp |
| 2011-03-31 | 5.60% | Rs1.43 Billion ≈ $15.44 Million |
Rs25.48 Billion ≈ $275.60 Million |
-0.19pp |
| 2010-03-31 | 5.79% | Rs1.14 Billion ≈ $12.31 Million |
Rs19.65 Billion ≈ $212.52 Million |
-3.68pp |
| 2009-03-31 | 9.47% | Rs1.58 Billion ≈ $17.07 Million |
Rs16.67 Billion ≈ $180.33 Million |
+3.45pp |
| 2008-03-31 | 6.01% | Rs760.99 Million ≈ $8.23 Million |
Rs12.66 Billion ≈ $136.90 Million |
+0.91pp |
| 2007-03-31 | 5.11% | Rs533.55 Million ≈ $5.77 Million |
Rs10.45 Billion ≈ $113.01 Million |
-- |
About Torrent Pharmaceuticals Limited
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-int… Read more